|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.9900 - 0.9900|
|52 Week Range||0.6500 - 3.5000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Carson City, Nevada--(Newsfile Corp. - November 12, 2019) - Pharmagreen Biotech, Inc. (OTC PINK: PHBI), is pleased to announce today that the company signed a term sheet for an Equity Purchase Agreement (the "Equity Agreement") with Oscaleta Partners LLC ("Oscaleta"), that should enable Pharmagreen to access capital over the next 2 years to support its current growth plans. The terms of the Equity Agreement will give Pharmagreen the right, but NEVER THE OBLIGATION, ...
CARSON CITY, NV, Oct. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has signed a Letter of Intent with Carpere Inc. for the supply of “CBD Dana” hemp starter plantlets for the 2020 farming season and beyond. The Pharmagreen team is excited to work with Carpere to be their supplier of all female high CBD hemp starter plantlets to produce the highest quality high CBD flower tops as well as production of the CBD whole hemp oils and isolate. Carpere owns and manages farmland, on behalf of farmers, in excess of 100,000 acres throughout Canada.
Enter Pharmagreen Biotech (PHBI). Pharmagreen is intent on raising the bar in the cannabis space, both in the quality of cannabis produced and the efficiency of the growing method. The company is highly focused on the rapidly evolving CBD industry by developing supply chain for CBD hemp growers utilizing the CBD Dana hemp strain.
CARSON CITY, NV, Sept. 3, 2019 /PRNewswire/ - Pharmagreen Biotech, Inc., (PHBI), is pleased to announce the formation of its independent advisory board and welcomes Dr. Archer Baskerville from Virginia, United States, and Dr. Wladyslaw Wojcik from Saskatchewan, Canada to serve as advisory board members and advising the Company on developments in the medical industry regarding the adaptation of cannabinoid use, especially CBD in the treatment of individuals. Both are currently practicing specialists in Cardiology and their professional insight will provide the company with very valuable data that will be used in future extraction and formulations of cannabinoids under the Pharmagreen brand. Pharmagreen is highly focused on the rapidly evolving CBD industry by developing supply chain for CBD hemp growers utilizing the CBD Dana hemp strain.
CARSON CITY, NV, July 23, 2019 /PRNewswire/ - Pharmagreen Biotech is pleased to announce it will use Signify's Philips GreenPower LED Lighting in our Cannabis Biotech Complex currently under development. The Cannabis Biotech Complex, located in Deroche, B.C., Canada once completed will be a high-tech, state of the art facility, and serve as a blueprint for additional future buildouts in United States and Internationally. The strategic supply partnership with Signify's Philips LED lighting technology adds the high-tech value and opens the door for future cooperation in advancing solutions for the tissue culture industry.
CARSON CITY, NV, July 18, 2019 /PRNewswire/ - Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), announced today that the Securities and Exchange Commission ("SEC") has declared effective the Company's registration on Form S-1 (file 333-230413) relating to the sale from treasury of up to 20,000,000 shares of the Company's Class A common stock at an issue price of $2 per share, and the resale of 4,051,725 common stock that have been issued to the Selling Stockholders named in this registration statement. Pharmagreen will not receive any proceeds from the re-sale of the securities by the selling security stockholders. Pharmagreen will receive the proceeds from the sale of the 20,000,000 shares issued out of treasury. The registration statement may be accessed through the SEC's website at www.sec.gov.
CARSON CITY, NV, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pharmagreen Biotech, Inc. (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has received notification concerning WFS PHARMAGREEN INC.’s application submitted under the Cannabis Regulations to become a license holder. “Health Canada has completed a preliminary and high-level review of the license application. Based on the information assessed, Health Canada has no critical concerns with the application at this time.” This confirms that all the required information submitted to date has been accepted by Health Canada.
CARSON CITY, NV, Feb. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has received notification from Health Canada that its cannabis licensing application under the Cannabis Act and the Cannabis Regulations to obtain a license at the proposed site in Deroche, British Columbia, Canada has advanced from the first stage, “Intake and Screening” to the second stage, “Detailed Review and Initiation of Security Clearance Process,” of a three stage process.
Carson City, Nevada--(Newsfile Corp. - January 29, 2019) - Pharmagreen Biotech, Inc. (OTC Pink: PHBI), is pleased to announce that its wholly owned Canadian Subsidiary, WFS Pharmagreen Inc., on January 25, 2019 executed an option agreement with Alliance Growers Inc. This option agreement provides Alliance Growers with an initial 10% equity interest in WFS Pharmagreen subsidiary 1155907 BC Ltd. for an investment of CDN $1,350,000 (received). The option also allows Alliance Growers to ...
CARSON CITY, NV, Jan. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pharmagreen Biotech, Inc. (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., has completed its migration to Health Canada's Cannabis Tracking and Licensing System, or CTLS. The CTLS is the Health Canada’s worldwide web portal that enables the submission of new license applications, request for amendments, and license renewals in addition to submission of monthly tracking reports. All submitted applications to Health Canada for the Access to Cannabis for Medical Purposes Regulations (ACMPR) prior to October 17, 2018 are required to migrate to the CTLS digital system on or before January 31, 2019. This new licensing system is designed to service the new recreational market while still including the provisions for supplying the medical cannabis license holders as was under the former application process in place prior to October 17, 2018.
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2018) - Alliance Growers Corp. (CSE: ACG) (FSE: 1LA) (WKN: A2DFYX) (OTCQB: ALGWF) ("Alliance" or "the Company") is pleased to announce that with the passing of the US 2018 Farm Bill by Congress legalizing the production of hemp, a form of cannabis with THC levels below 0.3%, conjunctively increased the U.S. market size for "CBD Dana" hemp tissue culture plantlets. Cannabidiol, or CBD, is ...
CARSON CITY, NV, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI) (“Company”) is pleased to announce that with the passing of the 2018 Farm Bill by Congress legalizing the production of hemp, a form of cannabis with THC levels below .3%, conjunctively increased the U.S. market size for “CBD Dana” hemp tissue culture plantlets. Cannabidiol, or CBD, is a compound found in cannabis that is popping up all over the U.S. market. Currently, CBD generates $418 million in sales, with expectations to increase to $1.6 billion by 2021, according to Brightfield Group. Pharmagreen’s Cannabis Biotech Complex, in the construction phase and slated for completion in Q1 of 2020, is focused on the production of cannabis tissue culture starter plantlets.
Carson City, Nevada--(Newsfile Corp. - November 27, 2018) - Pharmagreen Biotech, Inc., (OTC Pink: PHBI) ("Company") provided commentary on the burgeoning cannabis production market following its recent legalization October 17, 2018. Pharmagreen CEO Peter Wojcik provided the following observations in conjunction with how the Company believes its Cannabis Biotech Complex, currently under construction in B.C., Canada, will help solve the infancy stage production issues facing the sector."Recently published news indicates that several leading ...